Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID-19 vaccination: A case report.
Clin Case Rep
; 10(4): e05744, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-1797953
ABSTRACT
Coronavirus disease-19 (COVID-19) vaccines are massively administered globally and some adverse events, such as myocarditis, are being reported. Most of the reported cases of post-vaccination myocarditis have occurred following mRNA vaccinations. However, there have also been recent reports of myocarditis following adenovirus vector vaccinations. We present a case of a 32-year-old female patient who developed myocarditis following the administration of the first dose of the AstraZeneca vaccine. The patient developed inappropriate exertional tachycardia and exertional dyspnea from Day 3 and was diagnosed with myocarditis by subsequent echocardiography about 3 months later. We are unable to confirm a direct association between myocarditis and AstraZeneca vaccination. However, we would like to increase awareness regarding the possibility of developing myocarditis following AstraZeneca vaccination.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
Topics:
Vaccines
Language:
English
Journal:
Clin Case Rep
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS